Breaking News, Trials & Filings

Merck Serono Suspends Stimuvax Trials

Merck Serono has temporarily suspended the worldwide clinical development program for Stimuvax (BLP25 liposomal vaccine) due to an unexpected serious adverse reaction in a patient with multiple myeloma.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, have temporarily suspended the worldwide clinical development program for Stimuvax (BLP25 liposomal vaccine) due to an unexpected serious adverse reaction in a patient with multiple myeloma. The FDA has also placed a clinical hold on the IND application. The suspension of the Phase III clinical program for Stimuvax includes the START and INSPIRE trials in non-small cell lung cancer (NSCLC) and the STRIDE trial in brea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters